Royalty Report: Drugs, Nutraceutical, DHA – Collection: 145166

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Nutraceutical
  • DHA
  • Aquaculture
  • Food
  • Technical Know How
  • Agriculture Forestry & Fishing

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 145166

License Grant
The Company and Foundation agreed to a collaboration related to the research of aquaculture products.
License Property
Our aquaculture technology currently relies on our DHA biomass and by-products from our oil extraction process as raw material ingredients.

Aquaculture.  Larval fish, crustaceans (shrimp) and mollusks (oysters and clams), like humans, require certain dietary fats such as DHA and ARA for optimal growth and health.

Docosahexaenoic acid, commonly known as DHA, and Arachidonic acid, commonly known as ARA, which many researchers believe may enhance mental and visual development in infants and play a pivotal role in brain function throughout life.

Field of Use
The collaborative research and license agreements is to develop new high value aquaculture feeds.  The new enrichment feeds is based on proprietary DHA and ARA technology.

IPSCIO Record ID: 7792

License Grant
This is a settlement agreement in which Licensor had previously licensed and then transferred back certain technology relating to human applications for DHA developed by a third party.
License Property
Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, sperm, testicles and retina. It can be synthesized from alpha-linolenic acid or obtained directly from maternal milk or fish oil.

IPSCIO Record ID: 211865

License Grant
For the Intellectual Property License of Licensors Proprietary Technology, Licensor grants to the Licensee of the Netherlands,  a perpetual, exclusive, including as to Licensor, worldwide, non-assignable, sublicensable license under the Licensors Proprietary Technology, the Licensors R&D Patents, the Excluded Subject Matter and any amendments and updates thereof to make, use, have made, import, sell and offer for sale arachidonic acid or ARA Products and ARA Products combined with other products in the Licensee ARA Fields of Use and to make ARA Products for delivery to Licensor and to perform Extraction and RBD processing.  RBD means the combined processes of refining, bleaching and deodorizing Crude Oil.

The parties have developed certain complementary (and, in some cases, blocking) technology for the production, refining, and blending of arachidonic acid for use in infant formula to meet the nutritional needs of infants and as a potential nutritional supplement and/or food ingredient for young children, pregnant and lactating women, and adults generally. Licensor owns technology related to the manufacture and use of arachidonic acid and has certain issued patents and patents pending throughout the world, claiming certain processes for the manufacture of arachidonic acid, certain compounds and certain uses; and Licensee owns technology related to the manufacture of arachidonic acid and has certain issued patents and pending patent applications throughout the world, claiming certain processes for the manufacture of arachidonic acid, certain formulations for that product, certain compounds and certain applications. Licensor has also obtained certain governmental regulatory approvals for the use of arachidonic acid in infant formula.

Licensee shall use Licensors brand names and the Licensor trade name, solely on Licensors behalf and for Licensors benefit, on all shipments of ARA Products by Licensee to Licensor or any Licensor customer, pursuant to delivery or order instructions by Licensor to Licensee, and Licensee shall not attach any additional brand names, trademarks, trade names, logos or designations to any such shipment.

License Property
Licensors Proprietary Technology shall mean, collectively, all Licensor Patents and all Know-how necessary for or useful to the manufacture, processing or use of ARA Products that are, owned by Licensor or any Licensor Affiliate, and disclosed or required to be disclosed hereunder to Licensee including without limitation technology for the Extraction and RBD processing steps.

Arachidonic acid (ARA) is a polyunsaturated omega-6 fatty acid 20:4. It is structurally related to the saturated arachidic acid found in Cupuaçu butter.

Nutritional oils are comprised of fatty acid components, primarily arachidonic acid, commonly known as ARA.

Nutritional oils is used as ingredients in infant formula and foods, and as ingredients in, and encapsulated for use as, dietary supplements.

Many researchers believe that these fatty acids may enhance mental and visual development in infants and play a pivotal role in brain function throughout life.

Field of Use
Licensees ARA Fields of Use shall mean any Feed Products and other uses of ARA that are not for human oral consumption or for the purpose of providing ARA as a nutrient for humans.

Licensors ARA Fields of Use shall mean all ARA fields of use other than the Licensee ARA Fields of Use.

IPSCIO Record ID: 240569

License Grant
The Canadian Licensor hereby grants to Licensee a sole and exclusive license in the Territory to make, have made, use, have used, import, have imported, offer for sale, sell and have sold Licensed Products in the Field, with rights to grant sublicenses that are co-extensive with such license, under any and all Licensor Program Intellectual Property (including Licensor Improvements), and Licensors rights in Joint Program Intellectual Property. Licensee shall have the right to assign or otherwise transfer its rights in the license granted herein (or any part thereof) to its Affiliates. Notwithstanding any such assignment, Licensee shall be responsible for the activities, including all reporting and royalty obligations, of such Affiliates as if they were Licensee.

During the Research Term:
(a) Licensee hereby grants Licensor a fully-paid up, non-exclusive, royalty-free, worldwide license, without the right to grant sublicenses, under MARTEK Background Technology, MARTEK Program Intellectual Property (including MARTEK Improvements), and MARTEK’s interest in Joint Program Intellectual Property, for the sole purpose of conducting the activities required in the performance of its obligations hereunder as part of the R&D Program.

(b) Licensor hereby grants to Licensee a fully-paid up, non-exclusive, royalty-free, worldwide license, without the right to grant sublicenses, under SEMBIOSYS Background Technology, SEMBIOSYS Program Intellectual Property (including SEMBIOSYS Improvements), SEMBIOSYS’ interest in Joint Program Intellectual Property, and any relevant Third Party Licenses, for the sole purpose of conducting the activities required in the performance of its obligations hereunder as part of the R&D Program.

License Property
Licensed Product means any product or any part thereof, that (i) the production, manufacture, use or sale of which would infringe any Valid Claim contained in any patent rights licensed to Licensee by Licensor hereunder, or (ii) which is produced through the direct and material use of Licensor Program Know-How or Joint Program Know-How.

Program Intellectual Property means all Patent Rights and Program Know-How. Licensor Program Intellectual Property shall mean Licensor Patent Rights and Licensor Program Know-How. Licensee Program Intellectual Property shall mean Licensee Patent Rights and Licensee Program Know-How. Joint Program Intellectual Property shall mean Joint Patent Rights and Joint Program Know-How.

Licensor Improvements means (a) Inventions which claim (i) methods of transforming genes or expressing genes in plants or (ii) methods of making or using plant oil bodies, and (b) all Program Know-How other than Inventions that is directly-related to (a) above.

Licensee Improvements means (a) Inventions which claim the identification, composition or use (i) of DHA, EPA and/or ARA (arachidonic acid) synthesis genes or (ii) of supplemental genes used or evaluated in the course of performance of the R&D Program for enhancing DHA, EPA or ARA production in plants, and (b) all Program Know-How other than Inventions that is directly related to (a) above.

R&D Program means the research and development program to be conducted by Licensor and Licensee and which is described in the Workplans.

Field of Use
This collaboration agreement is to co-develop DHA products from plants.

Field means the production, manufacture and marketing of DHA, ARA and EPA produced in transgenic plants.  These fatty acids are docosahexaenoic acid, commonly known as DHA, and arachidonic acid, commonly known as ARA.  DHA and ARA may help develop the eyes and central nervous systems of newborns and promote adult mental and cardiovascular health.

IPSCIO Record ID: 27951

License Grant
The Licensee and the Canadian University, with the consent of the former Licensee, executed an agreement pursuant to which the Licensor authorized the Licensee to be substituted for the former Licensee in the License Agreement.
License Property
On May 1, 2001, the University and the Company have formalized this substitution for an exclusive, irrevocable worldwide license for the development, exploitation and marketing of the technologies and processes developed by, and belonging to, the University as part of the research it is conducting into devising an extraction and purification process for krill and/or calanus and/or crustaceans oil. The License Agreement also applies to oil extracted through this extraction process from krill and/or calanus and/or crustaceans.
Field of Use
The Licensee's OceanExtractTM is a cold extraction process that enables the extraction of Omega-3 polyunsaturated oil, protein concentrates and amino acid concentrates from marine biomasses such as krill, calanus and other crustaceans. Krill oil is extracted from the raw material, i.e. the krill, by successive immersions in organic solutions and through filtrations. The process allows them to obtain the biological benefits for high-end products currently sought after by the nutraceutical, cosmetics and pharmaceutical markets.

IPSCIO Record ID: 2911

License Grant
The Licensee entered into a License Agreement with the Licensor for certain patented technology expected to be used in the production of the Licensee's life’sDHA™. Under the Agreement, the Licensee was granted a perpetual and generally exclusive License to the technology.
License Property
Life’sDHA™ is a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements and animal feed.
Field of Use
The rights granted apply to baby food.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.